$0.08
$0.00 (0.00%)
End-of-day quote: 05/18/2024
ASX:ANP
Antisense Therapeutics Annual Report
| Year | Year | 2023 | 2022 | 2021 | 2020 | 2005 | 2004 | ||
|---|---|---|---|---|---|---|---|---|---|
| Rev. | Revenue |
|
$1.58M | $1.78M | $0.58M | $0.67M | $0.79M | $1.34M | |
| GM % | Gross Margin % |
|
97.91% | 96.31% | 80.91% | 69.51% | 75.35% | 91.43% | |
| OM | Operating Margin |
|
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | |
| EPS | Earnings Per Share |
|
$0.00 | $-0.02 | $-0.01 | $-0.01 | $-0.01 | $-0.18 | $-0.14 |
| Div. | Dividends |
|
$0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| PR % | Payout Ratio % |
|
-0.00% | -0.00% | -0.00% | 0 | -0.00% | -0.00% | |
| Sha. | Shares |
|
669.31m | 668.79m | 574.48m | 488.79m | 35.53m | 35.53m | |
| OCF | Operating Cash Flow |
|
$-8.15M | $-7.81M | $-5.83M | $-3.95M | $-5.59M | $-2.21M | |
| FCF | Free Cash Flow |
|
$-8.18M | $-7.81M | $-5.84M | $-3.96M | $-5.60M | $-2.23M | |
| FCFS | Free Cash Flow Per Share |
|
$-0.01 | $-0.01 | $-0.01 | $-0.01 | $-0.16 | $-0.07 |
